Clinical Trial Update: Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the immune response, safety, and reactogenicity of the RSVPreF3 OA vaccine when co-administered with PCV20 in older adults; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• PCV20 (20-valent pneumococcal conjugate vaccine)
• RSVPreF3 OA (RSV prefusion F protein vaccine for older adults)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2025-05-18